Results 51 to 60 of about 9,247 (168)

Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience

Cancer Reports
Background Daratumumab represents the first‐in‐class fully humanized monoclonal antibody that targets CD38 for the treatment of relapsed/refractory multiple myeloma (RRMM).
Oscar C. Y. Yang, Yi‐Hao Chiang, Caleb Gonshen Chen, Yu‐Cheng Chang, Ming‐Chih Chang, Huan‐Chau Lin, Johnson Lin, Ken‐Hong Lim   +7 more
doaj   +1 more source

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion

Asia-Pacific Journal of Oncology Nursing, 2018
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment ...
Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk   +7 more
doaj   +1 more source

Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials

Scientific Reports, 2021
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials
Szabolcs Kiss, Noémi Gede, Péter Hegyi, Bettina Nagy, Rita Deák, Fanni Dembrovszky, Stefania Bunduc, Bálint Erőss, Tamás Leiner, Zsolt Szakács, Hussain Alizadeh   +10 more
doaj   +1 more source

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy

British Journal of Haematology, EarlyView.
Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà, Angela Grassi, Valeria Ruocco, Carmine Liberatore, Edoardo Olivari, Martina Tinelli, Francesca Fazio, Sonia Morè, Emanuele Favero, Claudio Salvatore Cartia, Nicola Sgherza, Concetta Conticello, Roberto Mina, Martina Gherardini, Giuseppe Mele, Massimo Gentile, Anna Furlan, Massimiliano Arangio Febbo, Maria Livia Del Giudice, Ombretta Annibali, Bernardo Rossini, Edoardo Scomazzon, Marco Talarico, Enrica Antonia Martino, Claudio De Magistris, Francesca Fioritoni, Anna Maria Cafro, Laura Paris, Sara Pezzatti, Roberta Della Pepa, Paola Boggione, Giuseppe Pietrantuono, Valeria Tomarchio, Francesco Vassallo, Maria Luisa Pioltelli, Francesco Pisani, Antonia Cagnetta, Lorenzo De Paoli, Gabriele Buda, Elisabetta Antonioli, Monica Galli, Alberto Tosetto, Pellegrino Musto, Elena Zamagni, Francesca Patriarca, Silvia Mangiacavalli, Renato Zambello, Massimo Offidani, Maria Teresa Petrucci   +48 more
wiley   +1 more source

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Haematologica, 2020
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja Weisel, Michele Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios A. Dimopoulos   +18 more
doaj   +1 more source

Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management

European Journal of Haematology, EarlyView.
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson, Thórir Einarsson Long, Sigrún Thorsteinsdóttir   +2 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Haematologica, 2018
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or ...
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos   +36 more
doaj   +1 more source

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

European Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Brain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain, Annabelle Emery, Frankie F. Brown, Adam J. Causer, Rebecca Oliver, Rachel Eddy, Shoji Leach, John Graby, Daniel Augustine, Sally Moore, Josephine Crowe, James Murray, James E. Turner, John P. Campbell   +13 more
doaj   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source